Basilea Pharmaceutica Ag Stock Current Valuation
| BPMUF Stock | USD 52.83 0.00 0.00% |
Valuation analysis of Basilea Pharmaceutica helps investors to measure Basilea Pharmaceutica's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Undervalued
Today
Please note that Basilea Pharmaceutica's price fluctuation is very steady at this time. Calculation of the real value of Basilea Pharmaceutica is based on 3 months time horizon. Increasing Basilea Pharmaceutica's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Basilea pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Basilea Pharmaceutica AG. Since Basilea Pharmaceutica is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Basilea Pink Sheet. However, Basilea Pharmaceutica's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 52.83 | Real 61.88 | Hype 52.83 | Naive 53.28 |
The real value of Basilea Pink Sheet, also known as its intrinsic value, is the underlying worth of Basilea Pharmaceutica Company, which is reflected in its stock price. It is based on Basilea Pharmaceutica's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Basilea Pharmaceutica's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Basilea Pharmaceutica AG helps investors to forecast how Basilea pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Basilea Pharmaceutica more accurately as focusing exclusively on Basilea Pharmaceutica's fundamentals will not take into account other important factors: Basilea Pharmaceutica AG Company Current Valuation Analysis
Basilea Pharmaceutica's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Basilea Pharmaceutica Current Valuation | 724.26 M |
Most of Basilea Pharmaceutica's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Basilea Pharmaceutica AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Basilea Pharmaceutica AG has a Current Valuation of 724.26 M. This is 94.96% lower than that of the Healthcare sector and 84.41% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 95.64% higher than that of the company.
Basilea Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Basilea Pharmaceutica's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Basilea Pharmaceutica could also be used in its relative valuation, which is a method of valuing Basilea Pharmaceutica by comparing valuation metrics of similar companies.Basilea Pharmaceutica is currently under evaluation in current valuation category among its peers.
Basilea Fundamentals
| Return On Asset | 0.0261 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 724.26 M | |||
| Shares Outstanding | 11.93 M | |||
| Shares Owned By Insiders | 3.07 % | |||
| Shares Owned By Institutions | 29.13 % | |||
| Price To Earning | 200.00 X | |||
| Price To Sales | 4.09 X | |||
| Revenue | 148.12 M | |||
| Gross Profit | 30.89 M | |||
| EBITDA | 2.11 M | |||
| Net Income | (6.83 M) | |||
| Cash And Equivalents | 140.74 M | |||
| Cash Per Share | 11.89 X | |||
| Total Debt | 94.54 M | |||
| Current Ratio | 1.36 X | |||
| Book Value Per Share | (5.67) X | |||
| Cash Flow From Operations | (32.02 M) | |||
| Earnings Per Share | 0.25 X | |||
| Number Of Employees | 177 | |||
| Beta | 0.88 | |||
| Market Capitalization | 626.06 M | |||
| Total Asset | 247.27 M | |||
| Retained Earnings | (908 M) | |||
| Working Capital | 219 M | |||
| Current Asset | 283 M | |||
| Current Liabilities | 64 M | |||
| Z Score | -0.6 | |||
| Net Asset | 247.27 M |
About Basilea Pharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Basilea Pharmaceutica AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Basilea Pharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Basilea Pharmaceutica AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Basilea Pink Sheet
Basilea Pharmaceutica financial ratios help investors to determine whether Basilea Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Basilea with respect to the benefits of owning Basilea Pharmaceutica security.